News Releases - Arrakis Therapeutics
Jan 10, 2022 · Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform. February 05, 2020. Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery. November 21, 2019.
Amgen and Arrakis Therapeutics Announce Multi-Target …
THOUSAND OAKS, Calif. and WALTHAM, Mass., Jan. 11, 2022 – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Arrakis - Arrakis Therapeutics
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Amgen partners with Arrakis to develop drugs aimed at RNA
Jan 11, 2022 · Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massachusetts-based biotech $75 million in cash.
Arrakis Therapeutics to Present at Jefferies Healthcare Conference
Jun 1, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks one of the largest bets on RNA-targeting small molecule …
Arrakis Therapeutics Announces New Scientific Advisory Board …
Mar 23, 2021 · Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of …
Arrakis Therapeutics Enters Strategic Collaboration and License ...
Apr 8, 2020 · Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform. Arrakis Receives $190 Million Upfront Cash Payment with Potential for …
Arrakis Therapeutics signs drug discovery deal with Roche
Apr 9, 2020 · Arrakis Therapeutics has signed a collaboration and licence agreement with Roche to identify RNA-targeted small molecule (rSM) drugs against various targets in different therapeutic areas.